Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 6 - Studien 51 bis 60 von insgesamt 71
- Rekrutierung läuftA Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)
- Rekrutierung läuftKlinische Prüfung der Phase III von CPX-351 zur Behandlung von Kindern mit Myeloischer Leukämie mit Down-Syndrom 2018
- Rekrutierung läuftConstructing and validation of a robust, affordable, and widely applicable real-world outcome predictor for risk-tailored therapy for DLBCL patients in the German healthcare system
- Rekrutierung läuftA Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy
- Rekrutierung läuftAbemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer with focos on digital side effect managementMolekulare Marker
- Rekrutierung läuftNational acute promyelocytic leukemia (APL) observational study NAPOLEON‐Register der Deutschen AML IntergroupMolekulare Marker
- Rekrutierung läuftProspective multicenter registry for neonates, infants, children, adolescents, and adults with neuroblastic tumours.
- Rekrutierung läuft
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer [CR109264]
Molekulare Marker - Rekrutierung läuftPrävention von frühen Darmkrebserkrankungen - PEARL
- Rekrutierung läuftA randomized phase II study to evaluate the safety and efficacy of trastuzumab deruxtecan versus CDK4/6 inhibitor based endocrine therapy as first line therapy of HR-positive and HER2-low/ultralow advanced breast cancer patients classified as non-luminal subtype according to gene expression profiling